Antibody-mediated immunity plays a crucial role in protection against SARS-CoV-2 infection.
We isolated a panel of neutralizing anti-receptor-binding domain (RBD) antibodies elicited …

The emergence of numerous variants of SARS-CoV-2, the causative agent of COVID-19,
has presented new challenges to the global efforts to control the COVID-19 pandemic. Here …

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …

SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …

SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has
been spreading rampantly. The global scientific community has responded rapidly to …

Many studies have examined the impact of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants on neutralizing antibody activity after they have become dominant …

SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding
domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response …

Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are
specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …